Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Faron Pharmaceuticals (FARN) Share News

REPEAT: Faron Pharma half-year loss widens on higher R&D spending

25th Aug 2022 12:10

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widened, as the company reported higher research and administrative expenses and remained revenue-less. Read More

Faron Pharmaceuticals half-year loss widens on higher R&D spending

25th Aug 2022 11:43

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widen, as the company reported higher research and administrative expenses and remained revenue-less. Read More

UK earnings, trading statements calendar - next 7 days

18th Aug 2022 16:02

UK shareholder meetings calendar - next 7 days

30th Jun 2022 15:59

IN BRIEF: Faron raises EUR5 million for bexmarilimab development

28th Jun 2022 18:03

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Conducts private placing to raise EUR5 million in 2.0 million newly issued treasury shares at EUR2.49 each. Once the funds are received, Faron expects to have sufficient working capital to last until the first quarter of 2023. Net proceeds will be largely used for the acceleration of the clinical development program and manufacturing of bexmarilimab, its immunotherapy asset. Read More

IN BRIEF: Faron Pharma reveals topline results from MATINS trial

15th Jun 2022 19:24

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Announces top-line overall survival results from its phase 1/2 'Macrophage Antibody To Inhibit Immune Suppression study, which investigated the safety and efficacy of bexmarilimab monotherapy in ten different hard-to-treat or on operable solid tumour cohorts. Read More

IN BRIEF: Faron Pharma doses first patient in bexmarilimab study

8th Jun 2022 16:54

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Doses first patient in the phase I/II BEXMAB study. The study is investigating bexmarilimab, Faron's wholly-owned precision immunotherapy asset, in combination with azacitidine in multiple hematological malignancies. This marks the first time bexmarilimab is being assessed as part of a clinical study in hematologic malignancies, Faron explains. Read More

IN BRIEF: US and Finland approve Faron's bexmarilimab study

16th May 2022 17:35

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - US Food & Drug Administration and Finnish Medicines Agency clear company's investigational new drug application to start its BEXMAB study, which is for assessing the safety, tolerability and efficacy of precision cancer immunotherapy known as bexmarilimab. Read More

TRADING UPDATES: Belluscura to raise GBP5 million; React buys

12th May 2022 19:45

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

IN BRIEF: Faron Pharmaceuticals CEO buys shares worth EUR71,000

8th Apr 2022 19:30

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Chief Executive Markku Jalkanen buys 25,000 shares at an average price of EUR2.82, worth EUR70,533, on Tuesday. Read More

TRADING UPDATES: Rambler ups production; SRT Marine anticipates loss

5th Apr 2022 20:45

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

EARNINGS UPDATES: Everyman revenue doubles; Aeorema in interim profit

25th Mar 2022 13:21

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More

UK earnings, trading statements calendar - next 7 days

18th Mar 2022 16:09

IN BRIEF: Faron research sheds light on Covid-linked mutations

14th Mar 2022 14:14

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Publishes research expanding on analysis of a gene mutation in an interferon receptor that is linked to corticosteroid response and outcomes in acute respiratory distress syndrome and Covid-19 patients. Builds on Faron's findings from its phase III 'Interest' trial for Traumakine in ARDS patients. Traumakine is an investigational intravenous interferon beta-1a therapy. Read More

FTSE 100 Latest

Value10,600.53

Change-2.95